Related Experiment Video
Updated: Jun 17, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
Warfarin-induced skin necrosis
Seema Inayatullah1, Gautam Phadke, Leonid Vilenski
1MeritCare Health System, Department of Internal Medicine, University of North Dakota School of Medicine, Fargo, ND, USA.
Abstract:
There is a lack of guidelines regarding the selection of patients who need intravenous heparin, duration of intravenous heparin, and future use of warfarin in prevention and treatment of warfarin-induced skin necrosis. This case report emphasizes the challenges in dealing with vitamin K antagonists (VKA) therapy.
Insights
Guidelines are lacking for managing warfarin-induced skin necrosis, including heparin use and warfarin continuation. This case report highlights challenges in vitamin K antagonist therapy.
Area of Science:
- Cardiology
- Pharmacology
- Dermatology
Background:
- Warfarin therapy is crucial for preventing thromboembolic events but carries risks, including skin necrosis.
- Warfarin-induced skin necrosis (WISN) is a rare but severe complication requiring careful management.
- Current clinical guidelines for managing WISN are limited, particularly concerning anticoagulation strategies.
Observation:
- This case report details a patient experiencing warfarin-induced skin necrosis.
- The report focuses on the complexities of intravenous heparin administration and subsequent warfarin use.
- Challenges in patient selection and treatment duration for heparin were encountered.
Findings:
- A significant gap exists in established protocols for heparin selection and duration in WISN cases.
- Managing vitamin K antagonist (VKA) therapy presents considerable clinical challenges.
- The report underscores the need for clearer guidelines in preventing and treating WISN.
Implications:
- This case highlights the critical need for evidence-based guidelines in managing warfarin-induced skin necrosis.
- Improved understanding and protocols can enhance patient outcomes and reduce complications associated with VKA therapy.
- Further research is warranted to address the therapeutic uncertainties in WISN management.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Endocarditis II: Clinical Features of Infective Endocarditis